| Autor: |
Micek HM; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA., Visetsouk MR; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA., Fleszar AJ; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA., Kreeger PK; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA. kreeger@wisc.edu.; University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. kreeger@wisc.edu.; Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. kreeger@wisc.edu.; Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. kreeger@wisc.edu. |
| Abstrakt: |
High-grade serous ovarian cancer (HGSOC) is the most common and deadly subtype of ovarian cancer as it is commonly diagnosed after substantial metastasis has already occurred. The past two decades have been an active era in HGSOC research, with new information on the origin and genomic signature of the tumor cell. Additionally, studies have begun to characterize changes in the HGSOC microenvironment and examine the impact of these changes on tumor progression and response to therapies. While this knowledge may provide valuable insight into better prognosis and treatments for HGSOCs, its collection, synthesis, and application are complicated by the number of unique microenvironments in the disease-the initiating site (fallopian tube), first metastasis (ovary), distal metastases (peritoneum), and recurrent/platinum-resistant setting. Here, we review the state of our understanding of these diverse sites and highlight remaining questions. |
